Dermatology

With Epsolay treatment, inflammatory lesions of rosacea were reduced by nearly 70% by the end of both 12-week trials compared with a 38% to 46% reduction with the vehicle cream.

Ruxolitinib (Opzelura) is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis.

Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks.

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Abrocitinib (Cibinqo) is a Janus kinase inhibitor indicated for the treatment of adults with refractory moderate-to-severe atopic dermatitis.

Aftersun Aloe Vera naturally soothes sunburns, minor skin irritations, and abrasions.

Regeneron’s supplemental biologics license application for the drug targets patients aged 12 years and older.

Ruxolitinib (Opzelura; Incyte) is a Janus kinase inhibitor indicated for patients 12 years of age or older whose atopic dermatitis is inadequately controlled with topical prescription therapies or when those therapies are inappropriate.

Lidocaine is a local anesthetic that offers temporary relief of pain and itching.

Sirolimus is the first topical treatment to gain FDA approval for facial angiofibroma associated with tuberous sclerosis complex.

Calamine spray treats insect bites, rashes, minor skin irritations, and minor cuts.

Deucravacitinib is a possible solution for patients with psoriasis who wish to have the convenience of an oral medication.

The monotherapy demonstrates rapidly improved symptoms over 4 weeks for individuals with moderate-to-severe disease.

Johnson & Johnson’s Janssen Pharmaceutical Companies subsidiary’s post-hoc analysis of Tremfya demonstrates clinically significant improvements.

Study finds that the use of biologics and other potentially immunocompromising therapies for atopic dermatitis was associated with low risk of severe COVID-19.

Prurigo nodularis causes intense, persistent itch, with thick skin nodules that can cover most of the body.

Baricitinib (Olumiant; Eli Lilly and Incyte ) was found to produce significant hair regrowth on the scalp, eyelashes, and eyebrows of adults with severe alopecia areata.

Cortizone-10 is used to treat a variety of skin conditions.

In recent years, the auditing process has evolved into a full-blown investigation, often requiring pharmacies to submit hundreds of pages of documentation

Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis

Odor-Eaters foot powder removes foot odor and offers possible wetness protection.

Gold Bond Ultimate treats or prevents dry, rough, scaly, itchy skin, as well as minor skin irritations.

Ixekizumab (Taltz) is indicated for the treatment of conditions such as plaque psoriasis, psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Pharmacists can play a critical role in this therapy, panelists in a recent Pharmacy Times® Peer Exchange say.

If approved, Dipilumab will be the first biologic medicine available in the United States to treat uncontrolled moderate-to-severe AD for patients aged 6 months to 5 years.

Tralokinumab-ldrm is an interleukin-13 antagonist recently approved for the treatment of moderate-to-severe atopic dermatitis.

Sagely Naturals Pain Relief Cream combines CBD with powerful botanicals, peppermint, and menthol.

Ten quiz questions to assess your knowledge on common symptoms and treatments for psoriasis.

Tavaborole (Kerydin) is indicated for the topical treatment of onychomycosis of the toenails.

Ten quiz questions to assess your knowledge on common symptoms and treatments for atopic dermatitis.